PDCD1 and cancer: Indeed, monoclonal antibodies that bind to PD-L1, PD-1, or CTLA-4, known as immune checkpoint inhibitors (ICIs), are now being used for the treatment of multiple different human malignancies, which ultimately turn on the patient’s immune system to target their specific type of cancer [36].